Loading news...
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Shares of Biogen Inc. (NASDAQ: BIIB - Get Free Report) have earned an average recommendation of "Hold" from the twenty-seven brokerages that are covering the stock, MarketBeat Ratings reports. Fifteen research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
China Universal Asset Management Co. Ltd. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,570 shares of the biotechnology company's stock after selling 3,187 shares during the
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AlphaQuest LLC decreased its position in shares of Biogen Inc. (NASDAQ: BIIB) by 96.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375 shares of the biotechnology company's stock after selling 10,789 shares during the quarter. AlphaQuest LLC's holdings in
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair
Candriam S.C.A. lowered its stake in Biogen Inc. (NASDAQ: BIIB) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 158,821 shares of the biotechnology company's stock after selling 4,494 shares during the period. Candriam S.C.A. owned approximately 0.11%
State of Michigan Retirement System cut its stake in Biogen Inc. (NASDAQ: BIIB) by 85.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,103 shares of the biotechnology company's stock after selling 248,200 shares during the quarter. State of
Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings.
Biogen (BIIB) is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer's therapies, driving improved mix quality. BIIB's 2025 growth products generated $3.3B, offsetting MS declines; non-GAAP EPS exceeded guidance at $15.28, reflecting strong cost discipline and operational execution. Despite a guided mid-single-digit revenue decline in 2026, BIIB maintains robust earnings power, with key catalysts, including Leqembi expansion and potential high-dose Spinraza approval.
The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates.
Revenue: Total revenue for the full year 2025 was $9.9 billion, up 2% versus 2024.Non-GAAP EPS: Fourth quarter non-GAAP diluted EPS was $1.99; full year non-GA
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Biogen Inc. (BIIB) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $3.44 per share a year ago.
Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.